Pharvaris NVPHVS -2.39%22 3-Year RORE % is 6.70 as of Mar. 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,289 Biotechnology companies, Pharvaris NV ranks better than 70.52% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Pharvaris NV's 3-Year RORE % for the quarter that ended in Mar. 2026 was 6.70%.
The industry rank for Pharvaris NV's 3-Year RORE % or its related term are showing as below:
PHVS's 3-Year RORE % is ranked better than 70.52% of 1289
companies
in the Biotechnology industry
Industry Median: -11.44
vs PHVS: 6.70
Pharvaris NV (NAS:PHVS) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Pharvaris NV 3-Year RORE % Related Terms
Pharvaris NV 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHVS vs BHVN, NRIX, VCEL: 3-Year RORE % Comparison
For the Biotechnology subindustry, Pharvaris NV's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Pharvaris NV (PHVS) has a 3-Year RORE % of 6.70 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #380 out of 1289 companies in the Biotechnology industry, placing it in the top 29.5%.
Is Pharvaris NV's 3-Year RORE % too high?
Pharvaris NV's current 3-Year RORE % is 6.70. Based on the distribution chart, Pharvaris NV ranks #380 out of 1289 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's 3-Year RORE % compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #380 out of 1289 companies for 3-Year RORE %. This puts Pharvaris NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pharvaris NV and its competitors. Pharvaris NV's current 3-Year RORE % is 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current 3-Year RORE % of 6.70. The current 3-Year RORE % is 6.70. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current 3-Year RORE % is 6.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score
Get the complete analysis for PHVS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHVS has been successfully added to your 
